Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
5.
Artículo en Inglés | MEDLINE | ID: mdl-25994883

RESUMEN

BACKGROUND: Previous reports regarding the cutaneous adverse events of epidermal growth factor receptor inhibitors are mostly limited to small case reports and case series, mainly involving Caucasian patients. AIMS: We describe the trends in the clinical presentation of Asian patients who had cutaneous adverse events induced by epidermal growth factor receptor inhibitors and to explore the relationship between skin adverse events and tumor response. METHODS: From 2006 to 2010, medical records of Thai patients with non-small cell lung cancer receiving epidermal growth factor receptor inhibitors were retrieved and analyzed. RESULTS: In all, 99 patients were reviewed and analyzed. Erlotinib and gefitinib were commenced in 75 (75.8%) and 24 (24.2%) patients, respectively. Cutaneous adverse events occurred in 43 (57.3%) patients receiving erlotinib and in 15 (62.5%) patients receiving gefitinib. The most common adverse event was xerosis (52.5%). Less common adverse events included papulo-pustular eruption (27.3%), erythematous maculopapular rash (11.1%), mucositis (6.7%), paronychia (5.1%), and trichomegaly (2%). Elderly patients had a higher occurrence of xerosis. The presence of cutaneous adverse events was significantly higher in subjects who had a tumor response. LIMITATIONS: The limitations of study include its retrospective nature, and the initial screening of cutaneous adverse events was done by non-dermatologists. CONCLUSIONS: Cutaneous adverse events due to epidermal growth factor receptor inhibitors are not uncommon in the Asian population. We found a positive correlation between the occurrences of cutaneou adverse events and tumor response supporting the view that they are surrogate markers for therapeutic response.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Receptores ErbB/antagonistas & inhibidores , Clorhidrato de Erlotinib/efectos adversos , Neoplasias Pulmonares/tratamiento farmacológico , Quinazolinas/efectos adversos , Enfermedades Cutáneas Papuloescamosas/inducido químicamente , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Erupciones por Medicamentos/diagnóstico , Clorhidrato de Erlotinib/uso terapéutico , Femenino , Estudios de Seguimiento , Gefitinib , Humanos , Neoplasias Pulmonares/metabolismo , Masculino , Persona de Mediana Edad , Quinazolinas/uso terapéutico , Estudios Retrospectivos , Enfermedades Cutáneas Papuloescamosas/diagnóstico
7.
Artículo en Inglés | MEDLINE | ID: mdl-24177614

RESUMEN

Dowling Degos disease is a rare, reticulate pigmentary disorder with variable phenotypic expression that manifests as hyperpigmented macules and reticulate pigmentary anomaly of the flexures. Many variants of this condition and its overlap with other reticulate pigmentary disorders have been reported in the literature. We present here two cases of DDD with follicular localization, both clinically and histologically. It was associated with ichthyosis vulgaris in one case. Follicular DDD is an uncommon variant of this evolving dermatosis. Our report supports the possible role for disordered follicular keratinisation in its pathogenesis.


Asunto(s)
Hiperpigmentación/diagnóstico , Hiperpigmentación/terapia , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/terapia , Enfermedades Cutáneas Papuloescamosas/diagnóstico , Enfermedades Cutáneas Papuloescamosas/terapia , Adulto , Femenino , Humanos , Masculino , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/terapia , Adulto Joven
15.
Rev. bras. leprol ; 6(n.esp): 143-151, 1938. ilus
Artículo en Portugués | Sec. Est. Saúde SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1229980

RESUMEN

O A. refere a observação de um doente em que aparecêra erupção de máculas lepromatosas acompanhada de intensa descamação psoriasiforme. É o primeiro caso em que se observa êsse tipo de descamação. As máculas, no seu conjunto, lembravam as lesões tuberculoides e, no exame histológico, ao lado do infiltado lepromatoso era notada estrutura nodular sem gigantocitos. Os característicos clínico e histológico do caso, permitiam pensar na possibilidade de uma evolução da moléstia, do tipo lepromatoso para o nervoso tuberculoide. No entando, até o momento presente, foi obrigado a afastar essa possibilidade, em vista do resultado negativo da intradermo-reação de Mitsuda e porque duas biópsias ulteriores não confirmaram a primeira, sendo além disso fortemente positivos os esfregaços do material das máculas.


Asunto(s)
Enfermedades Cutáneas Papuloescamosas/clasificación , Enfermedades Cutáneas Papuloescamosas/diagnóstico , Lepra , Lepra/clasificación , Lepra/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA